David Minchin, Helium One CEO outlines Rukwa Phase 2 at London South East live event. Watch the full video here.
Always worth buying the dips and risk to reward is outstanding at the moment.
What lies ahead will be amazing. I am very confident that anything less the 80p is a great entry point at the moment until the deal is announced then it should be much higher.
Jenny this stock will likely have zero shorters the trend is up and we are due an imminent deal for Val 201. A few will always sell along the way and that is normal and is what causes small dips. The majority are buying as we are very cheap at the moment and news is soon to be announced.
Here is hoping for 74p run today leading into the big Monday.
I can see Physiomics and Merck work very closely with the software Physiomics use and Physiomics are part of our board. Could this link mean they are more likely to give greater value to the work done for Val 201 and 301 with closer negotiations which have resulted in a deal with Merck.
They have taken on 2 news drugs I wonder what those 2 drugs are. Could our partner be Merck if so we would shoot to the many £ mark very fast.
Something big is up and Monday is now one day away.
34 million market cap. Peanuts compared to our peers and where we should be. So much upside from here with limited downside following deal for Val 201.
Looks like something is up in the next day or two we shall soon find out. Good luck everyone.
Next week being the last week of October and then we got November. Cannot see a deal coming through in December or even late November. We are days away from a deal so surprising we have not even reached pre deal price of 70-80 p.
I think we will find many selling elsewhere to come here when the news arrives given our low market cap so this is a great entry level given the risk to reward ratio.
Here are my notes for newbies. As always do your own research as well.
Current market cap only 30 million. This is very, very low for a drug company with several clinical assets.
1) VAL 201 deal on track to be announced shortly. Upfront payments, massive milestones and royalties. Appears company will be a very large pharmaceutical which will also bring huge confidence.
2) Focus now on VAL 401 to get a deal here soon. Again expect a decent deal here after 201 deal.
3) Val 301 with Japanese for the last 17 months. Inbound queries from many other pharmaceuticals as confirmed in the meeting a few weeks ago. Deal highly likely here as well.
4) Cash spend is amongst the best on AIM for a drugs company. Strategy to out license future drugs means no risk of large placing. No placing planned for some considerable time. Should increase confidence.
5) Confirmed institutional investors are planned with Cenkos on board who will be supporting with this.
6) Lots of projects to be taken that will require low funding to be sold on at pre clinical stage for many millions if they show promise.
7) PYC work is almost complete and would likely have increased the value of our drugs significantly. Also potential findings for other treatments like other cancers or Sepsis.
8) PYC to get 6% of any deal. Cenkos 6% warrants from next year so will want share price to do well. Both on board as strong support.
9) First deal is decades will bring huge confidence here. Key note we only have 65 million shares therefore potential to rise quickly.
10) LIkely 201 will get to market based on lack of side effects, science and success rate so far. Therefore likely to be worth billions.
We have a great CEO and board that cares about the shareholders. No doubt big news will come shortly and the world will be jumping in. Fair price after deal is likely to be £1-£2 pound mark depending on finances and push on from here. I can see Val being many, amny £s in the next year or two with a very large market cap.
I am Keeping those shares because this will very likely be a once in a lifetime investment. The only way is up from this market cap with very, very low risk from here. Remember we are very cheap at the moment at a 30 million market cap and a deal likely to be about to be announced very soon. Strong support at any dips reduces any risk as well so a great investment here and now.
It's been a great few days. It is very positive that the shares are moving from non believers to believers and from weak holders to stronger holders at this level. I have actually been hoping that this would happen all year long. Also we allow those at lower prices to exit.
Now at a 30 million market cap and the pipeline we have with a deal here soon we should be at least 100 million market cap plus in the next few days/weeks. We should see a stronger rise and settle at a better price now that all this has happened.
So much to come we could have two quick deals one after the other and perhaps an operational update regarding PYC work and a new drug added in all in the next few weeks. Could be the explosive end to the year that we were all expecting. Great level to end and who knows VAL love an RNS on a Thursday.
30 Million market cap with 2 phase two drugs and a potential deal for Val 301 following the announcement of the deal for 201 shortly. if you compare to ours peers we have potential to multi bag as soon as the deal is announced in the coming days/weeks.
Tree Shakes – if you hold shares in a company and the price starts to drift downwards, you need to check two things. Firstly check the date and make sure it is not ex-dividend day – your share price will drop by the same amount as the dividend, and this is fine.
Secondly, scour the news for reasons why the sp might be dropping. If you can’t find any good reason, then the chances are that you are witnessing a “tree shake”. When a market maker is trying to fill a large institutional buy order, sometimes they may not have enough shares. They start to gradually drop the share price in order to “scare” people into thinking the company has a problem.
Weak holders will sell up, and the market maker continues to drop the price until enough weak holders have relinquished their shares. The market maker then fulfils its large order and returns the share price to where it started. Be eagle-eyed for all news relating to companies you hold shares in, and you’ll be better able to spot tree shakes and not get caught out.
@Bluecity Az deal with RedX although upfront payment will probably be less but Suzy confirmed that it will be enough working capital and that is all that matters. They are valued at 236 million and us at 30 million. The milestone payments will be priced in after the deal is announced to an extent.
At a market cap of only 30 million the only way is up. Treeshake and a bargain here.
Porky worth a try but maybe needs to happen immediately after she gets the deal as that will be a big result and she can speak about prostate cancer and women's health having secured a licensing deal. Then she has the name of the partner and financial details and should then get picked up.
Here is hoping for a big day. We are approaching the end of October and one wonders which day the news will drop. This really is a time now to take your positions if you do not want to miss out at this very cheap market cap and only about 65 million shares.
Porky since you use Twitter can you send a message to Tom Whipple, Sunday Times, Science Editor. Better to tweet him as they receive lots of emails. Let him know we have a female CEO who is working on cancer and women's health which is a rare area of research and has turned the company around following a deal with xxxx. Ask him to contact Suzy for further information.
This would attract a new investor base away from the day traders we get and will keep us at a good price.
Nothing to worry about one of the larger holders who is not a specialist in this area purchased back in the 6p range so sold a few as you would expect but is keeping most and will top slice along the way.
I think Adam Hargreaves is the largest holder and has added and has a very senior scientific background in drug development. He is purchasing at this price. Bottom line if you look any comparable deals they are worth some 100s millions in payments with our market cap being far below peer average. Other companies do not have 2 clinical phase 2 drugs in the pipeline and with a deal to be announced we are looking at a 100 million market cap as standard. Could be considerably higher depending on size and partner. Currently we are only 30 odd million.
We have a great CEO and strategy and once a deal is announced we will not be anywhere near current values. We know from all the interviews that it is simply a question of getting a signature and sorting some final bits before announcement. As always do your research by watching the interviews as this will prevent you selling early and missing out on an opportunity that is presented here.
Good luck and aim high because we are so undervalued with big news to come.
One of these days we will get a fierce rise before a deal. Between tomorrow and Friday I suspect we get to 70-80s then a deal will drop to take us 100, 150, 200p.
Great entry point at this low market cap with a very big deal for 201 lined up with limited downside from here. Deals are typically worth 100s millions in payments at various points.
@Porky totally agree. Imagine if it was a listed American company then £3 will be the new target but realistically decent shot of it being AZ who have experience in this field. That is what the board wanted and they did state they will pick one from many. Could be someone bigger.
Very healthy as few are selling and others are buying. On deal day we will rocket at the moment it is a gradual rise and rinse and repeat with new people taking positions and newer ones to come at a much higher price with a decent rise each time. All healthy and sets us up well for deal day when the wider market will come in big numbers.
Lots of buying over the last few days. Cenkos will know when the RNS will be released so could be getting some family and friends on board. All good. We are now very close to the announcement.
A few will sell along the way because they purchased at such a lower price and will miss out but it makes no difference because the real journey starts here and now.
100p first step to success and when the likes of Astrazeneca take 201 we could well see the investors from such companies coming over to us. They are very big buyers.
Move on from the past. We know the strategy here with the new board and a brilliant CEO. It's a new company and it is because of the past we have been so undervalued but the market will take a new birth when the first deal arrives.
We have everything to look forward to here. I can honestly see 74p hitting this week if a deal does not arrive this week but if it does then we almost certainly break the 100p mark. Great times.